PharmaJet

Executive Summary

PharmaJet is a privately held medical device company based in Golden, Colorado, that has developed a proprietary needle-free injection system. Founded in 2007, the company's technology delivers liquid medications intradermally or intramuscularly via a high-pressure, narrow stream, eliminating the need for needles. This approach offers several advantages: reduced needle-stick injuries, improved patient compliance (especially in needle-averse populations), and potential for more efficient vaccine and drug delivery. The system has applications across vaccines, biologics, and other injectable therapies, with a focus on areas where needle-free delivery can improve outcomes or simplify logistics, such as mass immunization campaigns. PharmaJet's needle-free technology has been validated through partnerships with pharmaceutical companies and public health organizations. The company has received regulatory clearances in various regions and has seen commercial adoption for vaccine delivery, including during the COVID-19 pandemic for influenza and other vaccines. The global needle-free injection market is projected to grow significantly, driven by increasing vaccination rates, a focus on healthcare worker safety, and technological advancements. PharmaJet is well-positioned to capitalize on this growth through ongoing collaborations and potential new product releases. However, as a private company, it faces competition from other needle-free devices and traditional injection methods, and its success depends on expanding commercial partnerships and achieving regulatory approvals in new markets.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Major Vaccine Manufacturer70% success
• Q2 2026FDA 510(k) Clearance for Next-Generation Device60% success
• Q4 2026Commercial Launch in Emerging Market for Vaccination Campaigns55% success